v3.26.1
Net Loss Per Share Attributable to Common Shareholders (Tables)
12 Months Ended
Apr. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders for the years ended April 30, 2026 and 2025:

 

 

Year Ended April 30,

 

 

2026

 

 

2025

 

Numerator:

 

 

 

 

 

Net loss attributable to Kestra Medical Technologies, Ltd.

$

(131,612

)

 

$

(113,814

)

Undeclared preferred dividends

 

 

 

 

(12,321

)

Net loss attributable to common shareholders

$

(131,612

)

 

$

(126,135

)

Denominator:

 

 

 

 

 

Weighted average shares of common share outstanding - basic and diluted

 

54,184,698

 

 

 

24,583,745

 

Net loss per share attributable to common shareholders - basic and diluted

$

(2.43

)

 

$

(5.13

)

Schedule of Dilutive Securities Excluded from Computation of Weighted Average Shares

The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):

 

 

As of April 30,

 

 

2026

 

 

2025

 

Stock options

 

4,504,508

 

 

 

4,649,100

 

Restricted stock units

 

2,499,958

 

 

 

Performance-based restricted stock units

 

434,702

 

 

 

Market-based restricted stock units

 

434,702

 

 

 

Restricted stock

 

25,640

 

 

 

32,485

 

Warrants to purchase Common Shares

 

109,069

 

 

 

434,916

 

Employee Stock Purchase Plan

 

68,142

 

 

 

Total

 

8,076,721

 

 

 

5,116,501